feed,title,long_url,short_url
Benzinga,NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy,https://benzinga.com/pressreleases/21/02/g19765414/nmpa-approves-toripalimab-in-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma-after-,
